Secondary Prophylaxis of Clostridium Difficile Infection
common.study.values.description
“Oral Vancomycin for Secondary Prophylaxis of Clostridium Difficile Infection (CDI)”
The purpose of this study is to gain further knowledge regarding the effectiveness of vancomycin prophylaxis in preventing Clostridium difficile infections in order to guide physicians' practices.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-yes
common.study.methods.is-healthy-no
Drug - Oral Vancomycin
Oral vancomycin 125mg twice a day prescribed for the duration of antibiotics
Placebo
Matched placebo twice a day prescribed for the duration of antibiotics
participant.views.study.view.additional
participant.views.study.view.scientific-title
A Randomized, Double-Blinded Placebo Controlled Study To Determine the Effectiveness of Oral Vancomycin for Secondary Prophylaxis of Clostridium Difficile Infection (CDI)
common.study.values.clinical-trial-id
NCT04000555
participant.views.study.view.id
dG6NJb
